GentiBio logo

GentiBio

Seattle, WA

GentiBio is a biotherapeutics company developing engineered regulatory T cells (EngTregs) programmed to treat autoimmune allergic diseases. The early-stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory, and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complementary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system. GentiBio is a Seattle, Washington-headquartered company launched in 2020 by Adel Nada, Chandra Patel, and Andy Walker.

gentibio.com

Company Details

Founded

2020

Employees

Between 100 - 200 employees

Raised

$177,000,000

Headquarters Location

Seattle, WA

Public

No

Acquired

No

CEO

Adel NadaAdel Nada

Founders

Chandra Patel
Chandra Patel
Andy Walker
Andy Walker
Adel Nada
Adel Nada

Company Collections

These are collections GentiBio is a part of. Click on the collection name to view similar companies.